Midatech Pharma Cash Flow - Quarterly (NASDAQ:MTP)

Add to My Stocks
$0.74 $0.01 (1.37%) MTP stock closing price Sep 20, 2018 (Closing)

The Midatech Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. While its important to look at the Midatech Pharma debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Midatech Pharma revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Midatech Pharma saw a cash impact of $7.38M from the issuance of MTP shares. The cash flow statement helps in the Midatech Pharma stock analysis by providing more information for evaluating changes in assets, liabilities and equities. The cash from operating activities for Midatech Pharma is $ 2017 Q4, which saw a decrease from previous quarter.

View and download details of Midatech Pharma cash flows for latest & last 40 quarters
show more
Fiscal year is Jan - Dec2017 Q42017 Q22016 Q42016 Q22015 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow3.29M1.63M5.9M3.08M1.12M
Net Increase (Decrease) in Assets Liabilities-1.85M-2.2M-0.16M-0.19M-1.36M
Cash From (used in) Discontinued Operations-----
Other Adjustments Net2.56M-0.81M3.85M-2.65M-3.31M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.91M-0.56M-1.82M-1.07M-1.4M
Acquisition Disposition of Subsidiaires-----1.01M
Increase (Decrease) in Investments-----
Other Cash Inflow (Outflow) from Investment Activities-0.98M-0.98M---
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares7.38M-21.09M--
Issuance (Repayment) of Debt Securities6M-0.12M-0.32M-0.23M-0.32M
Increase (Decrease) in Bank & Other Borrowings-----
Payment of Dividends & Other Cash Distributions-----
Other Cash from (used by) Financing Activities-0.14M--0.1M--0.01M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.33M-0.01M--0.2M-
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year21.92M3.93M---
Cash & Equivalents at Year End17.01M7.9M23.86M10.36M24.73M
All figures in USD. M: Millions of USD, B: Billions of USD.

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Midatech Pharma stock price history and Midatech Pharma stock comparison chart inevitably reflect its cash flow situation.

  • Midatech Pharma saw a positive change in Net Change in Cash and Cash Equivalents of $-5.67M till 2017 Q4. Apart from the Midatech Pharma stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Midatech Pharma decreased its cash from operating activities to $-16.69M till 2017 Q4. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a negative value of $-1.89M for MTP stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Midatech Pharma earned $13.24M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Midatech Pharma Cash Flow

Quarterly Cash Flow Statements For MLP & Strategic Equity Fund Inc Peers

CITIUS PHARMACT cash flow, NovaBay Pharma cash flow, Regulus Therapeutics cash flow, SHINECO INC cash flow